Seeking Alpha

intelligence » Comments |

Sort by:
Latest | Highest rated
  • Why I Sold My China Positions [View article]
    china is growing at 5% plus with a rising middle class--no other country is growing at this rate--these stocks are selling for less than 3 times earnings--look at CHCG ( China 3 C ) which has $32 million of cash or 60 cents per share and earnings of 50 cents a share--selling for 1 times earnings net of cash--AND IF YOU DIVIDE THE SALES VOLUME FOR THE THIRD QUARTER OF THIS YEAR BY THE NUMBER OF RETAIL STORES AND COMPARE TO THE SALES VOLUME LAST YEAR BY THE NUMBER OF STORES, AVE. STORE VOLUME INCREASED BY 15-20%--BAD SALE
    Nov 12 02:34 am |Rating: 0 -1 |Link to Comment
  • China Pharma Reports Improved Q3, Accounts Receivable Also Up [View article]
    AMEX price is $2 and not $3 which should be attainable
    Nov 11 08:18 am |Rating: 0 0 |Link to Comment
  • China Pharma Reports Improved Collection of Accounts Receivable  [View article]
    for some reason every time you report an article on this Company, it sounds positive but has a negative conclusion ---the positive cash flow is great AND THE COMPANY ONLY NEEDS A $2 STOCK FOR LISTING ON THE AMEX--SHOULD BE ATTAINABE WHEN THIRD QUARTER RESULTS ARE PUBLISHED
    Sep 23 09:31 am |Rating: 0 0 |Link to Comment
  • China 3C Group Hits Major Milestone [View article]
    the Company had $25 million of cash at Dec 30, 2007 and if it earns 45 cents this year, will have close to $1 per share by year end. With no debt, the Company will be selling for 1 times earnings net of cash
    Jun 27 07:25 am |Rating: 0 0 |Link to Comment
  • China Biotech Week in Review: Earnings, Deals and Drug Development [View article]
    Sales increased by 62%--naturally receivables increased

    bad debts went down--read the press release
    Jun 09 11:24 am |Rating: 0 0 |Link to Comment
  • Biotech in Review: Investment Capital for China Biopharma [View article]
    here you go again missing the good news on china pharma receivables
    1. reduced old receivables by more than 50%
    2. sales up 60% while receivables up ONLY half that amount
    3. bad debts not as bad as reservesd for originally

    all good news--and WHY IS THIS A BIOTECH STOCK-NEXT MAYBE INCLUDED IN JUST TECH
    May 05 10:45 am |Rating: 0 0 |Link to Comment
  • China Pharma's Q1 Impressive, But Collection Problems Are Worrisome [View article]
    ACCOUNTS RECEIVABLE UP ONLY 32% VERSUS SALES UP 62%-A VERY GOOD SIGN--AVERAGE DAYS OUTSTANDING FOR ACCOUNTS RECEIVABLE IS DOWN--A GOOD SIGN--DO THE MATH--SAME IS TRUE FOR BAD DEBTS--DOWN AS A % OF SALES
    May 01 08:03 am |Rating: 0 0 |Link to Comment
Comments by Ticker
intelligence's
Comments Stats
7 comments
Rating: -1 (0 - 1 is )